akayasu's arteritis (TA) is a nonspecific vasculitis of unknown etiology that primarily involves the aorta, its branches, and the pulmonary and coronary arteries. 1, 2 Geographic distribution is characteristic, as it mainly affects people in Asian and South American countries and 5,000 patients were listed on the basis of a governmentsponsored survey in Japan. 1 TA starts with acute inflammation, thus patients initially present with such symptoms as fever, malaise, and headache. Later, some cases undergo a clinical course of chronic inflammation, whereas others become senescent without signs of inflammation. Those with intractable symptoms have a more serious prognosis and suffer from additional complications such as thrombosis. 1, 3 Over the past several years, the link between inflammation and thrombosis has attracted renewed interest [4] [5] [6] [7] and it has been postulated that inflammatory cytokines within atheromatous plaque facilitate plaque rupture and acute thrombotic events. 8 Further, an increase in C-reactive protein (CRP) may be a marker of a guarded prognosis in patients with acute coronary syndrome. 9 Few studies have been conducted in regard to thrombogenicity in TA, of which some have indicated that there is altered coagulation cascade and platelet reactivity in patients with TA. [10] [11] [12] [13] Conventional methods were used in those studies for detecting platelet activation both in vivo (plasma -thromboglobulin, platelet factor 4, thromboxane B2 etc) and in vitro (platelet aggregation measured by optical densitometry), but they have limited value because of inherent technical problems. Furthermore, previous aggregation studies only investigated platelet -platelet interactions for the development of thrombosis, whereas recent developments in flow cytometric analysis have enabled the detection of specific markers for platelet activation, including P-selectin (CD62P), as well as the binding of fibrinogen and annexin V. 14, 15 To the best of our knowledge, flow cytometric analyses have not been done using platelets from patients with TA. To investigate the association of platelet activation with disease activity in TA using this advanced method, we determined platelet P-selectin expression and PAC-1 binding, a marker for GPIIb/IIIa activation, 16 in patients and healthy controls.
Methods

Study Population
Twenty-two female Japanese TA patients and 14 healthy age-and gender-matched controls (Group C: 26-74 years old) were enrolled in the study (Table 1) . Patients were diagnosed as having TA using criteria reported by the American College of Rheumatology. 17 The patients were classified into 2 groups: 9 had active disease (Group A: 26-71 years old) and 13 were inactive (Group I: 24-69 years old). The ratio of premenopausal to postmenopausal women (Table 1 ). In addition, none of the patients had received immunosuppressant therapy other than the corticosteroid. Five patients with active disease and 7 with inactive disease were diagnosed as having hypertension and took calcium blockers and/or angiotensin converting enzyme inhibitors. One patient each with active or inactive disease had hyperlipidemia although no lipid-lowering drugs were prescribed. One patient with active disease took sulfonylurea for diabetes mellitus. All subjects gave informed consent before enrollment. For an additional experiment, 4 healthy female volunteers (24-30 years, mean 26±3) were recruited, after giving informed consent, to investigate the effect of aspirin on the expression of platelet markers. Blood samples were collected before and after aspirin ingestion (81 mg/day, once after breakfast) for 7 days.
These investigations conformed to the principles outlined in the Declaration of Helsinki.
Sample Preparation
Venipuncture was performed in the antecubital vein and blood was drawn directly into a syringe containing 3.8% sodium citrate (9:1 vol/vol) using a 21-gauge needle. The first 3 ml of the sample was discarded using a 2-syringe technique, in order to reduce platelet activation to a minimum. 19 Immediately after sampling, each aliquot of blood was diluted 1:9 in HEPES buffer (in mmol/L: 10 HEPES, 136 NaCl, 2.7 KCl, 1 MgCl2, 0.47 NaH2PO4, 11.62 NaHCO3, 0.35% bovine serum albumin, pH 7.4). After stimulation with selected concentrations of ADP for 2 min, each aliquot was incubated for 20 min at room temperature with fluorescein-isothiocyanate (FITC)-conjugated PAC-1, phycoerythrin (PE)-conjugated anti-CD62P antibody and PerCP-conjugated anti-CD61 (GPIIIa) antibody. 20 Because CD61 is expressed in both resting and activated platelets, 20, 21 anti-CD61 antibody was used to identify platelet populations in the whole blood samples. The samples were kept at 4°C for at least 2 h after fixation in cold 1% paraformaldehyde. Platelets treated with ARG-GLY-ASP-SER (RGDS), anti-CD61 PerCP, and mouse IgG1-PE were used as negative controls.
Flow Cytometry
Within 24 h of collection, the samples were subjected to analysis of platelet activation using a flow cytometer (FACSCalibur, Becton Dickinson, San Jose, CA, USA). Platelet populations were identified by their characteristic light-scatter profiles and gated platelets were 95.9±4.3% (mean ± SD, n=22) positive for CD61. To quantify the degree of expression in platelets stimulated with ADP and in those that were not stimulated, 5,000 platelets were examined for FITC and PE fluorescence to calculate the mean fluorescence intensity (MFI) for both PAC-1 and anti-CD62P antibody.
Platelet Aggregation
Platelet aggregation in response to ADP was compared between Group A and Group I using a standard Born's method. 22 Fresh citrated whole blood samples were immediately centrifuged at 200 g (KS-5200C, Kubota, Tokyo, Japan) for 15 min at room temperature. The supernatant (platelet-rich plasma (PRP)) was transferred by plastic pipette to a polyethylene tube, which was then tightly capped. Platelet-poor plasma (PPP) was obtained by centrifuging the leftover sample at 2,000 g for 15 min. The platelet concentration in PRP was adjusted to 250,000 / l by adding PPP from each subject. Platelet aggregation was determined by optical densitometry (PAM-8T, Mebanix, Tokyo, Japan).
Statistical Methods
Statistical analysis was done by 2-or 1-way analysis of variance for repeated measures, with Scheffe's test for multiple comparisons, unless indicated otherwise; p<0.05 was considered significant.
Materials
PAC-1, FITC and anti-CD61 antibody PerCP were purchased from Becton Dickinson (San Jose, CA, USA). Anti-CD62P PE and mouse IgG1-PE were from Immunotech (Marseille, France). RGDS, ADP, and HEPES were from Sigma (St Louis, MO, USA). Paraformaldehyde was obtained from Wako Pure Chemical, Osaka, Japan.
Results
Whole Blood Flow Cytometry
In the resting state, there were no differences in MFI for both P-selectin expression and PAC-1 binding among the 3 groups. Following stimulation, the expression of P-selectin was significantly upregulated in Group A to 0.1-10 mol/L ADP as compared with Groups C and I (Fig 1) . Further, platelets from Group I patients did not show enhanced expression when compared with those from the controls. PAC-1 binding in response to ADP was similar among the 3 groups (Fig 2) . A representative profile is shown in Fig 3. The additional experiment to the main study revealed that taking aspirin for 7 days did not cause significant differences in MFI for P-selectin expression or PAC-1 binding in female volunteers (Fig 4) .
Platelet Aggregation
Results of platelet aggregation using ADP as agonist are shown in Table 2 . Platelet aggregation in response to 10 mol/L ADP was attenuated in Groups A and I as compared with Group C, despite no differences among the 3 groups in response to lower concentrations of ADP. No statistical differences in platelet aggregation were noted between Groups A and I.
Discussion
The salient feature of this study is that P-selectin expression, but not PAC-1 binding, was augmented in stimulated platelets in patients with active TA. The present results suggest that platelet -leukocyte interactions, rather than platelet -platelet, may be relevant to thrombotic complications in patients with active disease who receive conventional medication, including corticosteroid and aspirin. P-selectin is a member of the selectin family and resides in platelets and endothelial cells. It mediates the adhesion of activated platelets to neutrophils and monocytes via a specific interaction with P-selectin glycoprotein-1 5, 23, 24 and may trigger multiple intracellular events within leukocytes to promote vascular inflammation and facilitate atherosclerosis and thrombosis. [24] [25] [26] [27] Clinically, an increased expression of platelet P-selectin has been shown in patients with atherothrombotic diseases, including those in the acute phase of ischemic stroke 28 and with acute coronary syndrome. 29, 30 However, determination of platelet P-selectin and studies of platelet-monocyte interaction have not been performed in patients with TA.
It remains controversial whether patients in the inflammatory stage of TA are in a more thrombogenic state than those in the inactive stage. Akazawa et al 10 determined plasma levels of thrombin-antithrombin III complex, fibrinopeptide A, and D-dimer in 30 patients with TA and found that those parameters were increased significantly in patients as compared with control subjects. However, they did not observe any differences in these values between active (ESR ≥20 mm/h) and inactive (ESR <20 mm/h) patients, though detailed data, including age distribution, duration of illness, and percentage of patients receiving steroid and/or antiplatelet agents in the 2 subgroups, were not provided. In contrast, a recent study using transcranial Doppler ultrasonography revealed that more common microembolic signals were detected in patients with active TA than in those with the inactive form of the disease. 13 Further, a significantly higher prevalence of anti-monocyte antibodies 31 and elevation of serum interleukin 6 and RANTES (regulated on activation, normal T cell expressed and secreted) 32 have been reported in patients with active TA. Those molecules are synthesized mainly by activated monocytes and T lymphocytes. Thus, inflammatory responses associated with TA may provide lesions for activation of platelet Pselectin, which may lead to thrombotic complications.
Our study revealed that P-selectin expression in unstimulated platelets in patients with active TA was not enhanced. This result contrasts with some other studies that reported increase in P-selectin expression in resting platelets in patients with atherothrombotic diseases. [28] [29] [30] An important difference between our study and those other studies is that the present patients were not having or had had recent thrombotic attacks when enrolled in this study. Nevertheless, we found that platelet P-selectin expression was augmented in ADP-stimulated platelets in active TA patients. Although the mechanisms are not clear, platelets in these patients are supersensitive to ADP and this supersensitivity could help precipitate thrombotic events in which ADP plays an important role. 30, 33 Another finding of the present flow cytometric study was that PAC-1 binding was not different among active TA patients, inactive TA patients, and control subjects when the platelets were stimulated with ADP. Although the majority of patients were being treated with aspirin, aspirin intake for 7 days did not affect either PAC-1 binding or P-selectin expression in healthy volunteers (Fig 4) , as also reported previously. 34, 35 In contrast, platelet aggregation, another marker for platelet to platelet interaction, was attenuated in response to ADP (10 mol/L) in both active and inactive patients as compared with controls (Table 2) . It is wellestablished that aspirin, a cyclooxygenase inhibitor, inhibits thromboxane A2 synthesis and secondary aggregation responses triggered by a high concentration of ADP. Thus, it seems likely that differential effects of aspirin in the 2 assays are responsible for the apparent discrepancy of the results. Interestingly, disease activity made no difference to platelet aggregation in response to ADP. We speculate that a conventional regimen consisting of corticosteroid and aspirin for the treatment of TA is adequate for controlling the platelet -platelet response, but cannot overcome platelet -leukocyte interactions, which may be activated by vascular inflammation. If this is true, inhibition of platelet P-selectin may be an important therapeutic approach for TA to suppress inflammation and thrombosis. 36, 37 Study Limitations First, this was a cross-sectional study of a relatively small number of patients, with some differences in clinical background. Second, because of the low prevalence of TA, our findings are not supported clinically, because large clinical studies have not been performed to elucidate the effects of disease activity on prognosis or efficacy of antithrombotic agents against thrombotic complications. Further, basic studies on the role of platelet -leukocyte interaction are also lacking. Measuring platelet -leukocyte aggregates could provide supportive information for our findings. Third, the majority of the subjects were postmenopausal women and mean duration of illness exceeded 25 years. On the other hand, the subjects of our additional study (Fig 4) were younger than the subjects of the main study. In addition, all the study subjects were female although 10% of the patients with TA in Japan are males. 1 These age and gender bias could influence the results. 38, 39 In conclusion, P-selectin expression, but not activated GPIIb/IIIa, was augmented in ADP-activated platelets in patients in the active stage of TA with conventional therapy. Platelet P-selectin may play an important role in the inflammatory and thrombotic disease process associated with intractable TA by inducing platelet -leukocyte interactions.
